MGAT5 and neoplasm: We injected C57BL/6 mice with either 6694c2 EV or Mgat5-KO cells and treated tumor-bearing animals with a combination of PD-1– and CTLA4-blocking antibodies when tumors reached 50–100 mm3 in volume (Figure 6A).